Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 868–869 | Cite as

ASO Author Reflections: Outcomes of Gastroesophageal Neuroendocrine Tumors

  • Katherine D. Gray
  • Rasa ZarnegarEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. Scholar
  2. 2.
    Kulke MH, Shah MH, Benson AB, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13(1):78–108.CrossRefGoogle Scholar
  3. 3.
    Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6):751–757. Scholar
  4. 4.
    Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81(8):1351–1355. Scholar
  5. 5.
    Gray KD, Moore MD, Panjwani S, et al. Predicting survival and response to treatment in gastroesophageal neuroendocrine tumors: an analysis of the national cancer database. Ann Surg Oncol. 2018;25(5):1418–1424. Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryNew York Presbyterian Hospital—Weill Cornell MedicineNew YorkUSA

Personalised recommendations